Table 3.
Correlation of EPAS1 DNA variations with clinicopathological features of patients with esophageal squamous cell carcinoma.
| Features | Number | Amplification | Deletion | No change | P-value |
|---|---|---|---|---|---|
| Total patients | 80 | 36 (45.0%) | 34 (42.5%) | 10 (12.5%) | – |
| Sex | |||||
| Male | 67 (83.8%) | 33 (49.3%) | 26 (38.8%) | 8 (11.9%) | 0.19 |
| Female | 13 (16.2%) | 3 (23.1%) | 8 (61.5%) | 2 (15.4%) | |
| Age | |||||
| ≤60 | 54 (67.5%) | 22 (40.7%) | 25 (46.3%) | 7 (13.0%) | 0.53 |
| >60 | 26 (32.5%) | 14 (53.9%) | 9 (34.6%) | 3 (11.5%) | |
| Site | |||||
| Upper or middle | 53 (66.3%) | 19 (35.8%) | 25 (47.2%) | 9 (17.0%) | 0.03 |
| Lower | 27 (33.7%) | 17 (63.0 %) | 9 (33.3%) | 1 (3.7%) | |
| Size (cm) | |||||
| ≤6 | 31 (38.7%) | 12 (38.7%) | 12 (38.7%) | 7 (22.6%) | 0.09 |
| >6 | 49 (61.3%) | 24 (49.0%) | 22 (44.9%) | 3 (6.1%) | |
| Differentiation | |||||
| Well | 24 (30.0%) | 12 (50.0%) | 9 (37.5%) | 3 (12.5%) | 0.89 |
| Moderate | 39 (48.8%) | 18 (46.2%) | 16 (41.0%) | 5 (12.8%) | |
| Poor | 17 (21.2%) | 6 (35.2%) | 9 (53.0%) | 2 (11.8%) | |
| T-stages | |||||
| I | 3 (3.8%) | 2 (66.7%) | 1 (33.3%) | – | 0.02 |
| II | 3 (3.8%) | 1 (33.3%) | 2 (66.7%) | – | |
| III | 53 (66.2%) | 21 (39.6%) | 28 (52.8%) | 4 (7.6%) | |
| IV | 21 (26.2%) | 12 (57.1%) | 3 (14.3%) | 6 (28.6%) | |
| Lymph-node metastasis | |||||
| Presence | 60 (75.0%) | 29 (48.3%) | 22 (36.7%) | 9 (15.0%) | 0.14 |
| Absence | 20 (25.0%) | 7 (35.0%) | 12 (60.0%) | 1 (5.0%) | |
| Distant metastasis | |||||
| Yes | 5 (6.3%) | 2 (40.0%) | 3 (60.0%) | - | 0.43 |
| No | 75 (93.7%) | 34 (45.3%) | 31 (41.3%) | 10 (13.4%) | |
| Stage | |||||
| I & II | 22 (27.5%) | 8 (36.4%) | 13 (59.1%) | 1 (4.5%) | 0.12 |
| III & IV | 58 (72.5%) | 28 (48.3%) | 21 (36.2%) | 9 (15.5%) | |
Bold values indicates p-value of 0.05 or below.